Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMIND: TAA-T in Neuro-oncologic Disease
NCT03652545Phase 1Active, not recruiting
- Sponsor
- Catherine Bollard
- Start
- Dec 2018
- Primary completion
- Mar 2028
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label trial of TAA-CTL in diffuse intrinsic pontine glioma (DIPG) and central nervous system malignancy (2 arms), sponsored by Catherine Bollard. Primary endpoint: Incidence of Product-Related Adverse Events at 42 days. Started Dec 2018; status: active, not recruiting.
02
Drugs
TAA-CTL
03
Conditions
diffuse intrinsic pontine glioma (DIPG)central nervous system malignancy
Beyond the preview
Go deeper on NCT03652545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03652545.